COVID-19 has taught us a lot about minimizing our risk and focusing on wellness and prevention in our lives. Anita and John dig into what this shift means to the dietary supplements category of the consumer healthcare industry.
The Consumer Healthcare Products Association (CHPA) released a statement commending the House of Representatives following its passage of H.R. 1996, the SAFE Banking Act.
For its annual year-in-review series, Chain Drug Review featured CHPA's President & CEO, Scott Melville, who offered industry insights from last year and thoughts on the outlook for 2021.
This update includes any new statutes or laws passed in states regarding CBD labeling laws, as well as including any regulatory standards regarding CBD labeling laws in those states from spring to fall 2020.
Recognizing the urgent need to address confusion around the legal status of hemp and hemp-derived CBD, we call on Congress to provide FDA statutory authority and additional resources to regulate hemp and hemp-derived CBD as a dietary supplement.
The Consumer Healthcare Products Association released the following statement in response to the U.S. Food and Drug Administration report to Congress on the current cannabidiol marketplace.
CHPA today applauds the U.S. Food and Drug Administration for enforcing existing provisions in the Federal Food, Drug, and Cosmetic Act by sending warning letters to 15 companies illegally marketing cannabidiol products.
CHPA submitted this citizen petition to address the definition of a dietary supplement under section 201(ff) of the Federal Food, Drug and Cosmetic Act and to request that FDA establishes a regulatory pathway to legally market dietary supplements containing CBD.
